title: Efficacy of Compound Kushen Injection in Combination with Induction Chemotherapy for Treating Adult Patients Newly Diagnosed with Acute Leukemia.
abstract: We assessed the clinical effectiveness and safety of CKI (compound Kushen injection) plus standard induction chemotherapy for treating adult acute leukemia (AL). We randomly assigned 332 patients with newly diagnosed AL to control (n= 165, receiving DA (daunorubicin and cytarabine) or hyper-CVAD (fractionated cyclophosphamide, doxorubicin, vincristine, and dexamethasone)) or treatment (n= 167, receiving CKI and DA or hyper-CVAD) groups. Posttreatment, treatment group CD3+, CD4+, CD4+/CD8+, natural killer (NK) cell, and immunoglobulin (IgG, IgA, and IgM) levels were significantly higher than those of the control group (p< 0.05), and CD8+ levels were lower in the treatment group than in the control group (p< 0.05). Treatment group interleukin- (IL-) 4 and IL-10 levels were significantly higher compared to the control posttreatment (bothp< 0.05) as were complete remission, overall response, and quality of life (QoL) improvement rates (p< 0.05). The control group had more incidences of grade 3/4 hematologic and nonhematologic toxicity (p< 0.05). Responses to induction chemotherapy, QoL improvement, and adverse events incidence between control group patients with acute myeloid leukemia and acute lymphocytic leukemia were not significantly different. CKI plus standard induction chemotherapy is effective and safe for treating AL, possibly by increasing immunologic function.
authors.affiliation: Department of Clinical Hematology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province 430071, China.
authors.forename: Honglei
authors.initials: H
authors.lastname: Tu
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Lei
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China.
authors.forename: Shan
authors.initials: S
authors.lastname: Meng
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China.
authors.forename: Hailing
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Radiation and Medical Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province 430071, China.
authors.forename: Yongchang
authors.initials: Y
authors.lastname: Wei
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China.
authors.forename: Aili
authors.initials: A
authors.lastname: He
authors.affiliation: Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China.
authors.forename: Wanggang
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Clinical Hematology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei Province 430071, China; Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China.
authors.forename: Fuling
authors.identifier: 0000-0003-0982-0382
authors.initials: F
authors.lastname: Zhou